Which treatments are indicated for Female Pattern Hair Loss (FPHL)?

Female Pattern Hair Loss (FPHL), also known as androgenetic alopecia, is a common condition that affects women, particularly during and after the menopausal transition due to hormonal changes. The management of FPHL often involves various treatments that target the underlying hormonal factors contributing to hair loss.

Minoxidil, a topical treatment, is specifically approved for treating hair loss and works by increasing blood flow to hair follicles, promoting hair regrowth. It is one of the first-line treatments recommended for FPHL.

Spironolactone, an oral medication, has anti-androgenic properties, which can be beneficial as female pattern hair loss is influenced by androgens. Spironolactone can help in inhibiting the effects of androgens on hair follicles, making it a suitable treatment option for women experiencing hair loss.

Estrogen therapy may also serve as a supportive treatment, primarily when addressing hair loss in the context of menopause. Although estrogen itself is not directly indicated for hair regrowth like minoxidil, its use can restore hormonal balance and may have ancillary benefits for hair health.

In light of these treatments, it becomes clear why the choice indicating all of the above treatments is justified. Each option plays a role in addressing FPH